Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
about
Biochemical and Structural Characterization of Mycobacterium tuberculosis β-Lactamase with the Carbapenems Ertapenem and DoripenemDoripenem (Doribax): the newest addition to the carbapenemsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemPopulation pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Administration of Extended Infusion Piperacillin-TazobactamWith the Use of Smart Pump Technology.Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparatorsTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological AgePharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.Pharmacodynamic variability beyond that explained by MICs.Carbapenems: a potent class of antibiotics.The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities.In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.Doripenem: position in clinical practice.The use of carbapenems in the treatment of serious infections.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Recent advances in antibacterial drugs.Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.Evaluation of doripenem utilization and susceptibilities at a large urban hospital.Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.Characteristics of doripenem: a new broad-spectrum antibiotic.Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.Nosocomial infections: new therapeutic alternatives.Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
P2860
Q27660367-1C3B9A2D-395D-47C8-B141-BD874FD9F201Q28287288-83C97AEE-D2AC-45DB-9AF3-CDDA3B46E7F3Q28289744-3CCD7D8C-3508-496F-A53F-9177364A677BQ33553063-ADDE8598-DCAE-4411-A2BD-6AF6771BF9F7Q33774704-6B70BD1B-A23D-40A3-ABB4-C2C212A30C5BQ34026818-C9E0A6F3-BC44-436A-B6CA-A8D52653EE11Q34327857-AF8C36E5-F211-4892-A47C-D9D0FA580216Q35598403-4985982E-1DBA-473D-A4F4-0D64A5AB39A1Q35666586-01C3EED6-8091-440C-AD29-DF5090C969DBQ35859870-57B381EE-549B-4EA2-A23C-9F5D8C344259Q36313211-DE66139E-5420-4351-A0CD-144E934978CDQ36438971-596D65CC-EAB6-4A57-9DE9-431851138B1AQ36744871-63E239B2-A578-40A3-AFD2-E0AF4E1FAB31Q36757639-FC95F936-EE78-4160-876E-3F3A9367A795Q37030838-C47BB9AA-0684-423C-83DE-FF3B5E151411Q37098999-CB1F04BB-9C67-4FE9-9FF4-6607FB5D4F17Q37144843-88F9C531-70AE-4AC4-BE03-95B9C671C2A7Q37160369-8814C740-9F75-441F-8D38-6A07EB85A1ABQ37392734-3E25B3BF-62FF-4869-B814-151EA804DA90Q37503320-D86D13B4-37CA-4D53-B9AB-692BA0871F9AQ37555757-AA963766-52C3-48D7-846A-1383547ACF6CQ38073197-E093B629-CF3C-4B53-9909-3E851C882B79Q38115306-2ACC5C99-1756-42D8-9CD3-27C5F95C3F4CQ38405565-86C5D83F-CA14-48AC-956E-43B4D1F92938Q38751264-B24B3EEC-EFBF-4C25-97EB-5169B476EDA5Q39599930-B8AD5305-483C-4AF9-B242-FF8C39A01FFEQ40002163-922A8E3C-1823-473A-9779-272C035AB78DQ40749626-7DCCF920-EB79-4731-8608-6A2F52A33467Q42049594-9B3520D2-0760-41AE-A4A2-43F6D8E25BF0Q42259839-006F06C9-E7A7-49AE-AEEE-6C8BF345A1CDQ42819661-D968F507-52E2-4452-B6A4-7FEE9D5985DDQ43119954-439D34F9-A8AF-4D2A-A732-36D96C02D4A7Q43190490-4D2871E1-10F8-4A7A-A201-BD7445A8B65DQ43516275-C9FCE9A5-E8A4-41E8-B52E-961E12DC48CEQ45954223-2EAA2540-B8AE-4B4E-9CD1-83B353FB1B86
P2860
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@ast
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@en
type
label
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@ast
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@en
prefLabel
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@ast
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@en
P2093
P2860
P1476
Use of pharmacokinetic-pharmac ...... osing strategies for doripenem
@en
P2093
Brenda B Cirincione
Jeffrey P Hammel
Matthew A Wikler
Paul G Ambrose
Sujata M Bhavnani
P2860
P304
P356
10.1128/AAC.49.9.3944-3947.2005
P407
P577
2005-09-01T00:00:00Z